Urothelial carcinoma of the upper urinary tract diagnosed via FGFR3 mutation detection in urine: A case report

BMC Urology

Volumn 12, Issue , 2012, Pages

  Silverberg, Daniel M ^a  

^a NONE   (United States)

Author keywords

Bladder; Cancer; CertNDx; Diagnosis; FGFR3; Kidney; PCR; Renal pelvis; Ureter; Urothelial carcinoma

Indexed keywords

DNA; FIBROBLAST GROWTH FACTOR 3;

AGED; ARTICLE; AUTOLYSIS; CANCER DIAGNOSIS; CANCER GROWTH; CANCER SIZE; CANCER SURGERY; CANCER TISSUE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CYSTOSCOPY; DNA ISOLATION; EXON; FOLLOW UP; GENE MUTATION; GENETIC SCREENING; HUMAN; HUMAN TISSUE; KIDNEY CALYX; MALE; MUTATIONAL ANALYSIS; NEPHROURETERECTOMY; PREDICTIVE VALUE; REAL TIME POLYMERASE CHAIN REACTION; RETROGRADE PYELOGRAPHY; TRANSITIONAL CELL CARCINOMA; URETER DUPLICATION; URINALYSIS; URINE BASED GENETIC ASSAY; URINE CYTOLOGY;

EID: 84864562165     PISSN: None     EISSN: 14712490     Source Type: Journal    
DOI: 10.1186/1471-2490-12-20     Document Type: Article

References (17)

1. Epidemiology and risk factors for kidney cancer. Chow WH, Dong LM, Devesa SS, Nat Rev Urol 2010 7 245 257 10.1038/nrurol.2010.46 20448658
2. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Rouprêt M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, Babjuk M, Oosterlinck W, Eur Urol 2011 59 584 594 10.1016/j.eururo.2010.12.042 21269756
3. Imaging and staging of transitional cell carcinoma: part 2, upper urinary tract. Vikram R, Sandler CM, Ng CS, AJR Am J Roentgenol 2009 192 1488 1493 10.2214/AJR.09.2577 19457809
4. A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group. Brausi M, Witjes JA, Lamm D, Persad R, Palou J, Colombel M, Buckley R, Soloway M, Akaza H, Böhle A, J Urol 2011 186 2158 2167 10.1016/j.juro.2011.07.076 22014799
5. Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas. Cappellen D, De Oliveira C, Ricol D, de Medina S, Bourdin J, Sastre-Garau X, Chopin D, Thiery JP, Radvanyi F, Nat Genet 1999 23 18 20 10471491
6. Molecular grading of urothelial cell carcinoma with fibroblast growth factor receptor 3 and MIB-1 is superior to pathologic grade for the prediction of clinical outcome. van Rhijn BW, Vis AN, van der Kwast TH, Kirkels WJ, Radvanyi F, Ooms EC, Chopin DK, Boevé ER, Jöbsis AC, Zwarthoff EC, J Clin Oncol 2003 21 1912 1921 10.1200/JCO.2003.05.073 12743143
7. Combined microsatellite and FGFR3 mutation analysis enables a highly sensitive detection of urothelial cell carcinoma in voided urine. van Rhijn BW, Lurkin I, Chopin DK, Kirkels WJ, Thiery JP, van der Kwast TH, Radvanyi F, Zwarthoff EC, Clin Cancer Res 2003 9 257 263 12538478
8. Molecular grade (FGFR3/MIB-1) and EORTC risk scores are predictive in primary non-muscle-invasive bladder cancer. van Rhijn BW, Zuiverloon TC, Vis AN, Radvanyi F, van Leenders GJ, Ooms BC, Kirkels WJ, Lockwood GA, Boevé ER, Jöbsis AC, Zwarthoff EC, van der Kwast TH, Eur Urol 2010 58 433 441 10.1016/j.eururo.2010.05.043 20646825
9. Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors. Billerey C, Chopin D, Aubriot-Lorton MH, Ricol D, Gil Diez de Medina S, Van Rhijn B, Bralet MP, Lefrere-Belda MA, Lahaye JB, Abbou CC, Bonaventure J, Zafrani ES, van der Kwast T, Thiery JP, Radvanyi F, Am J Pathol 2001 158 1955 1959 10.1016/S0002-9440(10)64665-2 11395371
10. Fibroblast growth factor receptor 3 mutation analysis on voided urine for surveillance of patients with low-grade non-muscle-invasive bladder cancer. Zuiverloon TC, van der Aa MN, van der Kwast TH, Steyerberg EW, Lingsma HF, Bangma CH, Zwarthoff EC, Clin Cancer Res 2010 16 3011 3018 10.1158/1078-0432. CCR-09-3013 20404005
11. A simple and fast method for the simultaneous detection of nine fibroblast growth factor receptor 3 mutations in bladder cancer and voided urine. van Oers JM, Lurkin I, van Exsel AJ, Nijsen Y, van Rhijn BW, van der Aa MN, Zwarthoff EC, Clin Cancer Res 2005 11 7743 7748 10.1158/1078-0432.CCR-05- 1045 16278395
12. Sensitive detection of FGFR3 mutations in bladder cancer and urine sediments by peptide nucleic acid-mediated real-time PCR clamping. Miyake M, Sugano K, Kawashima K, Ichikawa H, Hirabayashi K, Kodama T, Fujimoto H, Kakizoe T, Kanai Y, Fujimoto K, Hirao Y, Biochem Biophys Res Commun 2007 362 865 871 10.1016/j.bbrc.2007.08.092 17803960
13. A non-invasive multi-analyte urine based diagnostic assay for urothelial cancer of the bladder in the evaluation of hematuria. Karnes RJ, Fernandez CA, Shuber AP, Mayo Clinic Proc 2012 (in press)
14. Khan AN, Transitional cell carcinoma imaging 2000 http://emedicine. medscape.com/article/381323-overview (accessed 09/13/11)
15. Urine markers for detection and surveillance of non-muscle-invasive bladder cancer. Tilki D, Burger M, Dalbagni G, Grossman HB, Hakenberg OW, Palou J, Reich O, Rouprêt M, Shariat SF, Zlotta AR, Eur Urol 2011 60 484 492 10.1016/j.eururo.2011.05.053 21684071
16. Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Lotan Y, Roehrborn CG, Urology 2003 61 1 109 118 10.1016/S0090-4295(02)02136-2 12559279
17. A novel approach to using matrix metalloproteinases for bladder cancer. Fernández CA, Wszolek MF, Loughlin KR, Libertino JA, Summerhayes IC, Shuber AP, J Urol 2009 182 2188 2194 10.1016/j.juro.2009.07.032 19758628